Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- USD | -.--% | -0,07% | +269,92% |
2019 | Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019 | |
2019 | Transcript : Dova Pharmaceuticals, Inc. - Special Call |
Omzet 2017 | - | Omzet 2018 | 10,36 9,69 | Marktkapitalisatie | 214 mln. 200 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -30 mln. -28,07 mln. | Nettowinst (verlies) 2018 | -72 mln. -67,36 mln. | EV/omzet 2017 | - |
Nettoliquiditeiten 2017 | 64,53 mln. 60,38 mln. | Nettoliquiditeiten 2018 | 84,34 mln. 78,91 mln. | EV/omzet 2018 | 12.500.634 x |
K/w-verhouding 2017 |
-20,6
x | K/w-verhouding 2018 |
-2,92
x | Werknemers | - |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 |
-
| Vrij verhandelbaar | 48,06% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mahmood Ladha
PSD | President | 60 | 12-11-19 |
Lee F. Allen
CTO | Chief Tech/Sci/R&D Officer | 72 | 01-04-17 |
Marc Banjak
LAW | General Counsel | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Henrik Stenqvist
BRD | Director/Board Member | 57 | 12-11-19 |
Guido Oelkers
BRD | Director/Board Member | 59 | 12-11-19 |
Director/Board Member | 55 | 12-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+269,92% | 808 mln. | |
-0,49% | 105 mld. | |
+3,31% | 97,5 mld. | |
+2,39% | 22,19 mld. | |
-16,16% | 21,33 mld. | |
-7,54% | 18,68 mld. | |
-41,41% | 16,6 mld. | |
-22,87% | 14,52 mld. | |
+6,32% | 14,09 mld. | |
+21,46% | 10,99 mld. |